ER with epoetin-α was 31.8% strictly applying IWG-2006 criteria, i.e., lower than ER generally reported in phase II trials with epoetin-α at similar dosing schedules in low- and intermediate-1-risk MDS patients [13–17]. Here, EPO is linked to myelodysplastic syndrome.